Other substances

Lividomycin

An aminoglycosidic antibiotic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Lividomycin is an aminoglycosidic antibiotic (Kobayashi et al., 1972).

Lividomycin on DrugBank
Lividomycin on PubChem
Lividomycin on Wikipedia

Synonyms

Lividomycin A

 

Structure image - Lividomycin

C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N

Supporting references

Link Tested on Impact factor Notes Publication date
Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment
in silico 2.08

In silico screening of ACE2 inhibitors.

 Jul/23/2020

AI-suggested references

Link Publication date
Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studies.
Sep/07/2021
Export (.csv)